CN1562297A - Combination of Chinese traditional medicine for curing vascular dementia and preparation method - Google Patents
Combination of Chinese traditional medicine for curing vascular dementia and preparation method Download PDFInfo
- Publication number
- CN1562297A CN1562297A CN 200410029883 CN200410029883A CN1562297A CN 1562297 A CN1562297 A CN 1562297A CN 200410029883 CN200410029883 CN 200410029883 CN 200410029883 A CN200410029883 A CN 200410029883A CN 1562297 A CN1562297 A CN 1562297A
- Authority
- CN
- China
- Prior art keywords
- radix
- weight portion
- weight portions
- vascular dementia
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating vascular dementia, improving memory and delaying sanility is prepared from rehmannia root, grass-leaved sweetflag rhizome, polygala root and notoginseng. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of vascular dementia and preparation method thereof, belong to medical technical field.
Background technology
In recent years, vascular dementia (Vascular Dementia, VD) be considered to cause second dull-witted reason, morbidity is only second to Alzheimer disease (AD), prevalence is between 0.9%～3%, account for 10%～50% of all dementias, be called as " century epidemic diseases ", so research and treatment VD are significant to the China that will step into aged society.
(Vascular Dementia is the carrying out property syndrome of intelligent disorder that produces behind the cerebrovascular VD) to vascular dementia, comprises the dementia that ischemic, hemorrhagic and cerebral hypoxia ischemia infringement cause.Primary disease is often referred to the dementia that is caused by ischemic cerebrovascular, as leukoaraiosis or Binswanger disease.Ischemia to a certain degree is not to be lethal for neurocyte.Blood flow is lower than the cerebral ischemia threshold value, can cause the change of brain function.Along with degree of ischemia further increases the weight of, the integrity of cell membrane can suffer damage, and necrosis can appear in neurocyte.At present, modern medicine does not still have the better prevention method to VD, yet many experimental results show, Chinese medicine has the conduction of the neurotransmitter of improvement, microcirculation improvement in the process of treatment of vascular dementia, improve Radical Metabolism, anti-apoptotic, the effect that regulator gene is expressed.
The inventor is on the basis that the efficacious prescriptions medicine is arranged of arrangement, excavation Chinese traditional treatment vascular dementia, and employing behavior pharmacological evaluation is screened the efficacious prescriptions medicine that has of Chinese traditional treatment vascular dementia, by a large amount of experimentatioies, filters out a prescription medicine.Theory of Chinese medical science is thought, deficiency of kidney-essence, brain (brain) lose to be supported, expectorant is turbid, blood stasis is tied mutually, stays in brain, cover to close clearly that dementia then appears in key, the present invention and Chinese traditional treatment dementia fill up kidney essense, blood stasis dispellingization is turbid, the collateral dredging rule of treatment of having one's ideas straightened out matches.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition for the treatment of vascular dementia;
Radix Rehmanniae Preparata 15～30 weight portion Rhizoma Acori Graminei 10～20 weight portion Radix Polygalaes 10～20 weight portions
Radix Notoginseng 10～20 weight portions
Press practice of pharmacy, preparation of pharmaceutical compositions of the present invention can be become various clinical acceptable forms, include but not limited to a kind of in the middle of the following dosage form: tablet, capsule, pill, granule, suspensoid, drop pill, oral liquid etc.
Another object of the present invention is to provide a kind of preparation method for the treatment of the Chinese medicine composition tablet of vascular dementia, and it is achieved by the following technical solution:
Radix Rehmanniae Preparata 15～30 weight portion Rhizoma Acori Graminei 10～20 weight portion Radix Polygalaes 10～20 weight portions
Radix Notoginseng 10～20 weight portions
Radix Polygalae is with 50%～70% ethanol merceration effective component extracting, cooling bath suction funnel sucking filtration, and control vacuum is taken out filtrate recycling ethanol at-0.1mPa; All the other flavour of a drug Radix Rehmanniaes Preparata, Rhizoma Acori Graminei, Radix Notoginseng are suitably pulverized, soaking after 0.5～1.5 hour water carries 2～3 times, add 10 times of water yields at every turn, extraction time is 0.5～1.5 hour, add the Radix Polygalae medicinal residues during last water extraction and fry in shallow oil altogether, merge decoction liquor, concentrate the back and add Radix Polygalae merceration concentrated solution, be adjusted to concentration and be 1.10～1.12, standby; The material extracts active ingredients of getting it filled liquid adds adjuvants such as dextrin, carboxymethyl starch sodium, mix homogeneously in the V-arrangement mixing tank, and wet granulation, oven dry back granulate adds lubricants such as magnesium stearate, and adjustment sheet is heavy, compression moulding.
Brain functioies such as study, memory and M-cholinergic transmitter are closely related, experiment shows, M cholinergic receptor-blocking agent scopolamine can cause mouse memory power obviously to descend under 5mg/kg dosage, the present invention then can obviously improve the memory ability of model mice, and the mechanism of action may to regulate neural activity relevant with scopolamine.Wherein Radix Notoginseng total arasaponins can be expanded the mice meningovascular, increase the hemoperfusion amount of brain microcirculation, reduce plasma viscosity, whole blood viscosity and the reduced viscosity of " blood stasis " mice, and then improve cerebral ischemia re-pouring mice potential learning memory ability and water maze memory acquisition and reproduction.
Through experimentation confirmation repeatedly, it is evident in efficacy that the present invention treats experimental vascular dementia animal, is better than at present the aniracetam and the gingko leaf preparation (Ginaton) of accepted treatment vascular dementia clinically.The present invention can improve the brain microcirculation, regulate neurotransmitter, improves activities of antioxidant enzymes, anti-apoptosis amount, has the memory ability of improvement, anti-aging effects, and also with the kidney essense of filling up of Chinese traditional treatment dementia, blood stasis dispellingization is turbid, and the collateral dredging rule of treatment of having one's ideas straightened out matches.
Following experimental example and embodiment are used to further specify the present invention.
Experimental example 1: the present invention is to the acquired amnemonic influence of mice
1. experiment purpose
Observe the present invention to the acquired amnemonic improvement effect of mice
2. materials and methods
2.1 animal and medicine
ICR kind mice, ♀ ♂ half and half, body weight 18～22g, available from Chinese Academy of Medical Sciences's animal center, the quality certification number: 0038935.Tablet of the present invention is provided by Beijing Normal University's resource medicine and natural resources of Chinese medicinal materials institute, aniracetam (Aniracetam) capsule, Wuxi Ai Xien pharmaceutical Co. Ltd, lot number: 010153-1; Folium Ginkgo extract sheet (EGb761), Dr Willmar Schwabe, lot number: 3061002; Scopolamine hydrobromide (scopolamine hydrobromide), Xuzhou Lai Si pharmaceutcal corporation, Ltd product, lot number: 030423.
Instrument: the program control camera bellows institute of Materia Medica,Chinese Academy of Medical Sciences system of keeping away of SBA-2 type; STT-2 type diving tower instrument institute of Materia Medica,Chinese Academy of Medical Sciences system.
2.2 grouping and administration
Animal is divided into matched group, model group (distilled water 20mlkg at random
-1Ig), aniracetam group (100mgkg
-1Ig), Folium Ginkgo extract group (40mg, kg
-1), tablet group (1800mgkg of the present invention
-1, 900mgkg
-1, 450mgkg
-1), totally 7 groups, every group of 14 mices, ♀ ♂ half and half.Each organizes mice every morning 9:00 administration 1 time.Successive administration 14 days.
2.3 model copy method
Memory acquisition disturbance model: 40min after the last administration, normal control group ip normal saline 10mlL
-1, all the other respectively organize the equal ip scopolamine of mice 2.0mgkg
-1, keep away dark behind the 10min or the diving tower training, once resurvey behind the 24h and test.
2.4 keep away dark experiment
Experimental provision is that (reflective box of 40cm * 12cm * 12cm) divides light and shade Room 2, and the hole of the about 3cm of a diameter is arranged between the Room 2, and all spread with the copper grid bottom, Room 2, and the copper grid of bottom, darkroom lead to the 36V electric current.Mice is put into bright chamber in the hole dorsad, and mice passes the hole and enters the darkroom and promptly shocked by electricity the bright chamber of can running back immediately.So training 5min writes down and is subjected to electricity irritation number of times (claiming errors number again) in every Mus 5min, and be incubation period by the time that bright chamber enters the darkroom first time.Remember behind the 24h and keep test: animal is placed bright chamber, and record is entered in time (incubation period) in electric darkroom and the 5min by bright chamber for the first time and is subjected to electricity irritation number of times (errors number).With errors number in the 5min and incubation period as school grade.
2.5 diving tower experiment
The diving tower device is the passive avoidance reflective box of 10cm * 10cm * 30cm, be divided into two with opaque dark plastic plate, the copper grid are arranged at the bottom of the case, but galvanization, the electro-insulating rubber platform that a high and diameter is 4.5cm is put at every right back angle, escapes the safety board of electric shock as mice.During experiment animal is placed on the electro-insulating rubber platform, adapt to 3min, pass to the 36V electric current then, animal skips on the copper grid and is promptly shocked by electricity, and its normal reaction is the rebound place of safety, contacts the copper grid simultaneously with two front foots and suffers that electric shock is wrong reaction, mice rests on (step-down latency incubation period on the platform, SDL) and escape incubation period on the platform (escape latency, EL), screening EL carries out data statistics the responsive mice of 2～60s.All train 5min during experiment, test behind the 24h, and the errors number in record SDL and the 3min (error number, EN).
2.6 statistical method
Data represent that with X ± SD utilization SPSS.10 statistical software relatively adopts one factor analysis of variance between group.
3. experimental result
Table 1 tablet of the present invention is kept away dark experimental result (X ± SD) to the acquired dysmnesia of scopolamine induced mice
The group training test
The dosage number of animals
(s) errors number incubation period incubation period (s) errors number
Blank group 14 42 ± 34 6.4 ± 0.3 180 ± 21 1.3 ± 0.2
Model group 14 66 ± 36 15 ± 6.2 76 ± 32 14.3 ± 8.2
Aniracetam group 100 14 57 ± 30 13.1 ± 2.2 124 ± 21 9.7 ± 4.9
Folium Ginkgo extract group 40 14 47 ± 29 12.9 ± 1.2 102 ± 28 8.0 ± 3.1
Tablet group 1,800 14 54 ± 41 14.6 ± 1.5 128 ± 24 9.8 ± 4.4 of the present invention
900 14 49±31 13.1±1.4 111±20 8.3±3.3
450 14 60±35 14.2±1.2 139±25 11.2±5.4
Table 2 tablet of the present invention is to the acquired dysmnesia diving tower of scopolamine induced mice experimental result (X ± SD)
The group training test
The dosage number of animals
(s) errors number incubation period incubation period (s) errors number
Blank group 14 53 ± 35 4.3 ± 1.6 31 ± 23 2.6 ± 1.3
Model group 14 66 ± 29 4.7 ± 2.1 48 ± 33 4.3 ± 2.8
Aniracetam group 100 14 54 ± 37 4.6 ± 2.6 40 ± 25 3.9 ± 2.1
Folium Ginkgo extract group 40 14 51 ± 28 3.9 ± 1.7 34 ± 26 2.9 ± 2.7
Tablet group 1,800 14 62 ± 39 4.8 ± 2.4 43 ± 28 3.2 ± 1.5 of the present invention
900 14 67±30 4.3±2.1 36±23 3.4±1.7
450 14 53±34 4.9±2.9 44±24 4.1±2.2
4. data analysis
According to table 1,2 data, learn by statistics and handle, the result is as follows, normal control group and model group and other six groups relatively, incubation period, errors number have the highly significant diversity, illustrate that modeling is successfully; Incubation period before and after the treatment of 5 administration groups, there were significant differences for errors number, illustrates that three kinds of medicines all have therapeutical effect to the acquired dysmnesia of scopolamine induced mice.Relatively there were significant differences for tablet high dose group wherein of the present invention and Folium Ginkgo extract group and its excess-three group, and tablet high dose group of the present invention and Folium Ginkgo extract group do not have significant difference, high dose tablet of the present invention is described when the acquired dysmnesia of treatment scopolamine induced mice, identical with the Folium Ginkgo extract curative effect.
Experimental example 2: tablet of the present invention causes the influence of disturbance of intelligence to the mice transient ischemic attack
1. experiment purpose
Observe tablet of the present invention causes disturbance of intelligence to the mice transient ischemic attack improvement effect
2. materials and methods
2.1 animal and medicine
With experimental example 1
Instrument: the program control camera bellows institute of Materia Medica,Chinese Academy of Medical Sciences system of keeping away of SBA-2 type; STT-2 type diving tower instrument institute of Materia Medica,Chinese Academy of Medical Sciences system; The program control water maze of SMG-2 type institute of Materia Medica,Chinese Academy of Medical Sciences system
2.2 grouping and administration
Animal is divided into matched group, model group (distilled water 20mlkg at random
-1Ig), aniracetam group (100mgkg
-1Ig), Folium Ginkgo extract group (40mg, kg
-1), tablet group (1800mgkg of the present invention
-1, 900mgkg
-1, 450mgkg
-1), totally 7 groups, every group of 14 mices, ♀ ♂ half and half.Each organizes mice every morning 9:00 administration 1 time.Successive administration 14 days.
2.3 model copy method
Transient ischemic attack causes the disturbance of intelligence model: 40min after administration in the 7th day, 3.5% chloral hydrate 350mg/kg ip anesthesia, model group, cut skin in the neck, separate exposure bilateral common carotid arteries (noting not damaging vagus nerve), bulldog clamp presss from both sides simultaneously and closes bilateral common carotid arteries, and the 20min that clocks is logical again, skin suture, postoperative is normally raised.Sham operated rats: only do the bilateral common carotid arteries exclusion, do not carry out ischemia-reperfusion.
2.4 behavioristics's method of testing: adopt that the SBA-2 type is program control keeps away that camera bellows, STT-2 type diving tower instrument and the program control water maze of SMG-2 type carry out the spatial memory ability to mice and learning and memory can be tested.
2.5 keep away dark experiment
With experimental example 1
2.6 diving tower experiment
With experimental example 1
2.7 water maze laboratory
Postoperative rose on the 2nd day, carried out water maze training, and after animal was familiar with twice on platform, trained 1 time morning and afternoon in every animal per sky, trained continuously 6 days, obtained the time and the distance of swimming of the 8th day and the 14th day respectively.
2.8 statistical method (with experimental example 1)
3. experimental result
Table 3 tablet of the present invention causes disturbance of intelligence to the mice transient ischemic attack and keeps away dark experimental result (X ± SD)
Group
Training test
The dosage number of animals
(s) errors number incubation period incubation period (s) errors number
Blank group 14 53 ± 32 6.7 ± 2.4 168 ± 31 2.4 ± 1.0
Model group 14 72 ± 31 13.4 ± 5.8 73 ± 41 12.5 ± 6.8
Aniracetam group 100 14 59 ± 29 12.0 ± 3.5 153 ± 24 8.6 ± 3.4
Folium Ginkgo extract group 40 14 63 ± 34 14.1 ± 6.2 160 ± 19 6.4 ± 2.9
Tablet group 1,800 14 71 ± 36 13.9 ± 4.1 159 ± 23 6.8 ± 1.6 of the present invention
900 14 65±26 16.4±3.8 134±27 8.7±4.8
450 14 59±43 15.8±5.7 139±37 10.3±6.6
Table 4 tablet of the present invention causes disturbance of intelligence diving tower experimental result (X ± SD) to the mice transient ischemic attack
Group
Training test
The dosage number of animals
(s) errors number incubation period incubation period (s) errors number
Blank group 14 108 ± 35 4.15 ± 1.6 95 ± 25 2.08 ± 0.9
Model group 14 96 ± 29 4.20 ± 1.6 124 ± 31 4.23 ± 1.9
Aniracetam group 100 14 53 ± 44 3.91 ± 1.9 43 ± 35 2.18 ± 1.1
Folium Ginkgo extract group 40 14 59 ± 34 4.39 ± 1.7 42 ± 30 2.71 ± 1.0
Tablet group 1,800 14 50 ± 25 4.62 ± 1.3 43 ± 29 2.45 ± 1.5 of the present invention
900 14 88±40 4.13±2.2 89±38 2.64±1.7
450 14 54±28 4.75±2.9 67±26 2.81±1.6
Table 5 tablet of the present invention causes disturbance of intelligence water maze laboratory result (X ± SD) to the mice transient ischemic attack
Group the 8th day the 14th day
The dosage number of animals
(s) distance of swimming time time (s) distance of swimming
Blank group 14 89 ± 36 951 ± 462 51 ± 41 834 ± 310
Model group 14 91 ± 47 969 ± 478 79 ± 45 960 ± 410
Aniracetam group 100 14 87 ± 52 868 ± 453 63 ± 29 720 ± 238
Folium Ginkgo extract group 40 14 96 ± 72 920 ± 361 59 ± 38 832 ± 276
Tablet group 1,800 14 94 ± 57 951 ± 345 56 ± 34 795 ± 257 of the present invention
900 14 81±43 941±412 63±37 810±284
450 14 95±47 879±483 65±26 795±256
4. data analysis
According to table 3,4,5 data, it is as follows to learn result by statistics, before and after 5 treatment group treatments significant difference is arranged all, mice water maze laboratory tablet high dose group of the present invention and Folium Ginkgo extract group, aniracetam group be P＜0.01 relatively, illustrates that tablet high dose group of the present invention causes and is better than Folium Ginkgo and aniracetam group in the disturbance of intelligence water maze laboratory improving the mice transient ischemic attack.
The preparation of embodiment 1 tablet of the present invention
Radix Rehmanniae Preparata 20g Rhizoma Acori Graminei 15g Radix Polygalae 10g Radix Notoginseng 10g
Radix Polygalae with the cooling bath sucking filtration, reclaims concentrated with 20g 60% ethanol merceration effective component extracting;
All the other flavour of a drug Radix Rehmanniaes Preparata, Rhizoma Acori Graminei, Radix Notoginseng are suitably pulverized, and soak, and water carries twice, add the Radix Polygalae medicinal residues during water extraction for the second time and fry in shallow oil altogether, merge decoction liquor, concentrate the back and add Radix Polygalae merceration concentrated solution, are adjusted to concentration and are 1.10-1.12, and be standby;
The material extracts active ingredients of getting it filled liquid adds starch, dextrin etc., and mix homogeneously is granulated, and oven dry back granulate adds magnesium stearate lubricant, and adjustment sheet heavily is 0.3 gram, is pressed into 15 altogether and makes finished product.
Embodiment 2
The tablet of the present invention of preparation is used for the treatment of vascular dementia among the embodiment 1.
Embodiment 3
The tablet of the present invention of preparation is used to improve memory ability among the embodiment 1.
Embodiment 4
The tablet of the present invention of preparation is used for defying age among the embodiment 1.
Claims (8)
1. Chinese medicine composition for the treatment of vascular dementia is characterized in that said composition is made up of following raw materials by weight proportions:
Radix Rehmanniae Preparata 3～6 weight portion Rhizoma Acori Graminei 2～4 weight portion Radix Polygalaes 2～4 weight portions
Radix Notoginseng 2～4 weight portions.
2. a kind of Chinese medicine composition for the treatment of vascular dementia as claimed in claim 1 is characterized in that the best proportioning of each crude drug is in the said composition:
Radix Rehmanniae Preparata 4 weight portion Rhizoma Acori Graminei 3 weight portion Radix Polygalaes 2 weight portions
Radix Notoginseng 2 weight portions.
3. as claim 1,2 described a kind of Chinese medicine compositions for the treatment of vascular dementia, it is characterized in that can be made into clinical acceptable forms and comprise tablet, capsule, pill, granule, suspensoid, drop pill, oral liquid.
4. the preparation method of a kind of tablet as claimed in claim 3 is characterized in that this method is:
Radix Rehmanniae Preparata 3～6 weight portion Rhizoma Acori Graminei 2～4 weight portion Radix Polygalaes 2～4 weight portions
Radix Notoginseng 2～4 weight portions
Radix Polygalae is with 50%～70% ethanol merceration effective component extracting, cooling bath suction funnel sucking filtration, and control vacuum is taken out filtrate recycling ethanol at-0.1mPa; All the other flavour of a drug Radix Rehmanniaes Preparata, Rhizoma Acori Graminei, Radix Notoginseng are suitably pulverized, soaking after 0.5～1.5 hour water carries 2～3 times, add 10 times of water yields at every turn, extraction time is 0.5～1.5 hour, add the Radix Polygalae medicinal residues during last water extraction and fry in shallow oil altogether, merge decoction liquor, concentrate the back and add Radix Polygalae merceration concentrated solution, be adjusted to concentration and be 1.10～1.12, standby; The material extracts active ingredients of getting it filled liquid adds adjuvant, mix homogeneously in the V-arrangement mixing tank, and wet granulation, oven dry back granulate adds lubricant, and adjustment sheet is heavy, compression moulding.
5. the preparation method of a kind of tablet as claimed in claim 4 is characterized in that this method is:
Radix Rehmanniae Preparata 4 weight portion Rhizoma Acori Graminei 3 weight portion Radix Polygalaes 2 weight portions
Radix Notoginseng 2 weight portions
Radix Polygalae is with 60% ethanol merceration effective component extracting, cooling bath suction funnel sucking filtration, and control vacuum is taken out filtrate recycling ethanol at-0.1mPa; All the other flavour of a drug Radix Rehmanniaes Preparata, Rhizoma Acori Graminei, Radix Notoginseng are suitably pulverized, soaking after 1 hour water carries 2 times, add 10 times of water yields at every turn, extraction time is 1 hour, for the second time add the Radix Polygalae medicinal residues during water extraction and fry in shallow oil altogether, merge decoction liquor, concentrate the back and add Radix Polygalae merceration concentrated solution, be adjusted to concentration and be 1.10～1.12, standby; The material extracts active ingredients of getting it filled liquid adds adjuvant, mix homogeneously in the V-arrangement mixing tank, and wet granulation, oven dry back granulate adds lubricant, and adjustment sheet is heavy, compression moulding.
6. as claim 1, the application of 2 described a kind of Chinese medicine compositions in the treatment vascular dementia.
7. as claim 1,2 application of described a kind of Chinese medicine composition in improving memory ability.
8. as claim 1,2 application of described a kind of Chinese medicine composition in defying age.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410029883 CN1256126C (en) | 2004-03-31 | 2004-03-31 | Combination of Chinese traditional medicine for curing vascular dementia and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410029883 CN1256126C (en) | 2004-03-31 | 2004-03-31 | Combination of Chinese traditional medicine for curing vascular dementia and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562297A true CN1562297A (en) | 2005-01-12 |
| CN1256126C CN1256126C (en) | 2006-05-17 |
Family
ID=34481023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410029883 Expired - Fee Related CN1256126C (en) | 2004-03-31 | 2004-03-31 | Combination of Chinese traditional medicine for curing vascular dementia and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1256126C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332688C (en) * | 2005-05-17 | 2007-08-22 | 刘升胜 | Medication for treating dementia in blood vessel type, and preparation method |
| CN101824447A (en) * | 2009-03-02 | 2010-09-08 | 中国水产科学研究院东海水产研究所 | Method for extracting nucleic acid from red-tide dinoflagellate |
| CN103285188A (en) * | 2012-02-22 | 2013-09-11 | 吉林省中医药科学院 | Traditional Chinese medicine composition tonifying qi and kidney and invigorating blood circulation and preparation method thereof |
| CN104688974A (en) * | 2015-04-02 | 2015-06-10 | 河南中医学院 | Traditional Chinese medicine electuary for treating alzheimer disease |
| CN110742972A (en) * | 2019-11-14 | 2020-02-04 | 美国琛蓝营养制品股份有限公司 | Traditional Chinese medicine composition with cognitive improvement effect and preparation method thereof and traditional Chinese medicine preparation |
-
2004
- 2004-03-31 CN CN 200410029883 patent/CN1256126C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332688C (en) * | 2005-05-17 | 2007-08-22 | 刘升胜 | Medication for treating dementia in blood vessel type, and preparation method |
| CN101824447A (en) * | 2009-03-02 | 2010-09-08 | 中国水产科学研究院东海水产研究所 | Method for extracting nucleic acid from red-tide dinoflagellate |
| CN103285188A (en) * | 2012-02-22 | 2013-09-11 | 吉林省中医药科学院 | Traditional Chinese medicine composition tonifying qi and kidney and invigorating blood circulation and preparation method thereof |
| CN103285188B (en) * | 2012-02-22 | 2015-11-18 | 吉林省中医药科学院 | Chinese medicine composition that a kind of vital energy benefiting and the kidney invigorating is invigorated blood circulation and preparation method thereof |
| CN104688974A (en) * | 2015-04-02 | 2015-06-10 | 河南中医学院 | Traditional Chinese medicine electuary for treating alzheimer disease |
| CN104688974B (en) * | 2015-04-02 | 2018-08-14 | 河南中医学院 | A kind of instant particles as Chinese medicine for treating senile dementia |
| CN110742972A (en) * | 2019-11-14 | 2020-02-04 | 美国琛蓝营养制品股份有限公司 | Traditional Chinese medicine composition with cognitive improvement effect and preparation method thereof and traditional Chinese medicine preparation |
| CN110742972B (en) * | 2019-11-14 | 2021-12-24 | 甘肃琛蓝生物医药有限公司 | Traditional Chinese medicine composition with cognitive improvement effect and preparation method thereof and traditional Chinese medicine preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1256126C (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857329A (en) | Preparing method of Chinese medicine composition with starch | |
| CN101045087A (en) | Traditional Chinese medicine for improving memory of learning and preventing memory failing | |
| CN1562297A (en) | Combination of Chinese traditional medicine for curing vascular dementia and preparation method | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN1824101A (en) | Xingsuerchen medicinal preparation and its new preparation method | |
| CN1879799A (en) | Menstruation-regulating preparation with asiabell and cassia bark and method for preparing same | |
| CN1927296A (en) | Chinese medicine composition for treating cervical and lumbar disc disease | |
| CN1775271A (en) | Hyperfunction-inhibiting preparation and new preparing method | |
| CN1775266A (en) | Qianjin cough-relieving preparation and new preparing method | |
| CN1899387A (en) | Method for preventing and treating child convulsion and its preparing method | |
| CN1827159A (en) | Menstruation-regulating preparation and novel method for preparing the same | |
| CN1810278A (en) | Enteric coated Chinese medicine composition for treating cervical and lumbar spondylopathy | |
| CN1562145A (en) | Guangsheng hemp extract, its preparing method and use | |
| CN1569197A (en) | Chinese medicinal soft capsule and preparing process thereof | |
| CN1559525A (en) | Red tangerine peel medicine for treating sputum cough and its preparation method | |
| CN1245999C (en) | Use of seguinii in preparing medicine or food | |
| CN1141137C (en) | Chinese medicine injection for stopping cancer pain | |
| CN1742798A (en) | Wuhaiyingliu preparation and new preparing method | |
| CN1593439A (en) | Orally disintegrating tablet of notoginsen total saponins and its preparation | |
| CN1626210A (en) | Preparation of 'Sanjin' medication for treating diseases of urinary system and preparation method | |
| CN1543968A (en) | Drug prepared by mulberry bark extract | |
| CN1879867A (en) | Formulation and its preparation process | |
| CN1709340A (en) | Medicinal composition for nourishing heart-disney, invigorating brain and tranquilizing mind, and its preparing method and use | |
| CN1939398A (en) | Use of gentiin in analgesic for treating arthritis | |
| CN1562210A (en) | Burnet disintegration tablet of mouth and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060517 Termination date: 20130331 |